Top 50 Biotechnology Startup Investors in United States (November 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
429 | United States, China, Canada | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | $25k–$5M |
|
SOSV SF & NY (Fka IndieBio)
VC Fund
|
274 | United States, United Kingdom, Canada | Seed, Pre-Seed, Convertible Note | Biotechnology, Health Care, Medical | $50k–$5M |
|
ARCH Venture Partners
VC Fund
|
170 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $9.1M–$230M |
|
Alexandria Venture Investments
VC Fund
|
128 | United States, Canada, France | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $12M–$148M |
|
OrbiMed
VC Fund
|
117 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $8M–$160M |
|
Alumni Ventures
VC Fund
|
113 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $850k–$75M |
|
Atlas Venture
VC Fund
|
106 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $750k–$115M |
|
New Enterprise Associates
VC Fund
|
99 | United States, China, India | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.7M–$100M |
|
Polaris Partners
VC Fund
|
96 | United States, Ireland, Singapore | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $5M–$105M |
|
Google Ventures
VC Fund
|
95 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$125M |
|
Khosla Ventures
VC Fund
|
93 | United States, United Kingdom, India | Series A, Seed, Series B | Artificial Intelligence, Software, Health Care | $1.6M–$100M |
|
RA Capital Management
VC Fund
|
84 | United States, United Kingdom, China | Series B, Post-IPO Equity, Series A | Biotechnology, Health Care, Therapeutics | $20M–$275M |
|
Third Rock Ventures
VC Fund
|
82 | United States, Japan, Israel | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$190M |
|
F-Prime
VC Fund
|
81 | United States, China, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $1.6M–$112M |
|
Versant Ventures
VC Fund
|
79 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$107M |
|
Gaingels
VC Fund
|
79 | United States, Canada, United Kingdom | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Health Care | $72k–$35M |
|
Andreessen Horowitz
VC Fund
|
71 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $1.5M–$116M |
|
5AM Ventures
VC Fund
|
69 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $13M–$110M |
|
MPM Capital
VC Fund
|
67 | United States, Canada, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$116M |
|
Innova Memphis
VC Fund
|
67 | United States, Germany, Argentina | Seed, Pre-Seed, Convertible Note | Health Care, Medical, Medical Device | $25k–$1.5M |
|
Canaan Partners
VC Fund
|
64 | United States, Israel, United Kingdom | Series A, Series B, Seed | Software, Biotechnology, Health Care | $1.8M–$75M |
|
Fifty Years
VC Fund
|
62 | United States, Germany, Canada | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $572k–$40M |
|
Connecticut Innovations
VC Fund
|
61 | United States, Israel, Canada | Seed, Series A, Venture - Series Unknown | Health Care, Biotechnology, Software | $100k–$23M |
|
Lux Capital
VC Fund
|
61 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.5M–$150M |
|
DCVC
VC Fund
|
58 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $1M–$130M |
|
Liquid 2 Ventures
VC Fund
|
54 | United States, Mexico, Canada | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | $125k–$48M |
|
Flagship Pioneering
VC Fund
|
53 | United States, Canada, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $6.6M–$230M |
|
The Column Group
VC Fund
|
53 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $15M–$120M |
|
BioAdvance
VC Fund
|
50 | United States, Canada | Seed, Series A | Biotechnology, Health Care, Medical | $350k–$40M |
|
KdT Ventures
VC Fund
|
50 | United States, India, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $2.6M–$175M |
|
TCA Venture Group
VC Fund
|
50 | United States, Canada, South Africa | Seed, Venture - Series Unknown, Convertible Note | Health Care, Software, Biotechnology | $100k–$6.2M |
|
8VC
VC Fund
|
49 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $2.5M–$175M |
|
Apple Tree Partners
VC Fund
|
49 | United States, Canada, United Kingdom | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.5M–$100M |
|
Founders Fund
VC Fund
|
48 | United States, United Kingdom, Germany | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.6M–$100M |
|
Novartis Venture Fund
VC Fund
|
48 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$107M |
|
Pfizer Venture Investments
VC Fund
|
47 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $12M–$120M |
|
Sand Hill Angels
VC Fund
|
47 | United States, Canada, India | Seed, Convertible Note, Series A | Software, Health Care, Biotechnology | $300k–$25M |
|
Casdin Capital
VC Fund
|
47 | United States, China, France | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $8.1M–$191M |
|
Deerfield
VC Fund
|
47 | United States, United Kingdom, Canada | Series A, Series C, Venture - Series Unknown | Health Care, Biotechnology, Medical | $3M–$120M |
|
Keiretsu Forum
VC Fund
|
46 | United States, India, Turkey | Venture - Series Unknown, Seed, Series A | Health Care, Software, Biotechnology | $65k–$8.1M |
|
Mission BioCapital
VC Fund
|
45 | United States, Switzerland, France | Series A, Series B, Venture - Series Unknown | Biotechnology, Health Care, Therapeutics | $2M–$350M |
|
Dolby Family Ventures
VC Fund
|
45 | United States, Austria, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Software | $2M–$65M |
|
Omega Funds
VC Fund
|
45 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Hatteras Venture Partners
VC Fund
|
45 | United States, Canada | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $5M–$88M |
|
Lightspeed Venture Partners
VC Fund
|
44 | United States, India, China | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $2M–$125M |
|
Life Science Angels
VC Fund
|
43 | United States, Israel, The Netherlands | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Medical | $1M–$10M |
|
Refactor
VC Fund
|
43 | United States, United Kingdom, New Zealand | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $2.7M–$103M |
|
Novo Holdings
VC Fund
|
42 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
Keiretsu Capital
VC Fund
|
42 | United States, Canada, India | Series A, Convertible Note, Seed | Health Care, Biotechnology, Software | $50k–$12M |
|
Cultivation Capital
VC Fund
|
41 | United States, Australia, Canada | Seed, Series A, Venture - Series Unknown | Software, Health Care, SaaS | $475k–$15M |
| Access all 10937 investors in United States Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV offers pre-seed capital and follow-on financial support to startups focusing on deep technology and scientific innovation. Founders utilize purpose-built laboratory facilities and engineering spaces to accelerate product development and testing. The firm facilitates connections between entrepreneurs and a network of investors through structured matchmaking events and technology summits.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, China, Canada
Investor stats
- Total investments: 3821
- Round size: Seed $125k–$5M; Pre-Seed $25k–$1.5M; Convertible Note $50k–$3.6M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $306M in 2023
Portfolio highlights
- Halla — Halla Intelligence is a digital solution that leverages over 100 billion shopper and product data points to recommend and promote what grocery items.
- Verdex Technologies — Verdex Technologies is an advanced materials platform technology that uses nanofibers to disrupt industries. Verdex doesn't just compete, it innovates and disrupts.
- Samphire Neuroscience — Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women.
IndieBio, re-named SOSV SF and SOSV NY in 2026, are two of SOSV’s three deeply resourced facilities for deep tech founders. The third is SOSV's HAX, in Newark, NJ. SOSV is the most active deep tech venture capital firm globally.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 676
- Round size: Seed $250k–$5M; Pre-Seed $50k–$525k; Convertible Note $150k–$950k
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- FluoSphera — Fluosphera better predicts the effects of molecules through animal-free microphysiological systems, helping you to discover more efficient drugs with less adverse side effects.
- Giraffe Bio — Giraffe Bio uses AI and biomolecules to optimize metal extraction, increase yield, and reduce environmental impact. Revolutionizing sustainable mining technology.
- Transition Metal Solutions — Transition harnesses wild microbial communities to recover copper and other critical metals from low-grade mining resources.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 485
- Round size: Series A $9.1M–$213M; Series B $14M–$230M; Series C $15M–$167M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $3B in 2024
Portfolio highlights
- Oratomic — Oratomic is a Pasadena-based quantum computing company building fault-tolerant quantum computers with neutral atoms.
- Synchron — The endovascular brain computer interface.
- Soufflé Therapeutics — Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Canada, France
Investor stats
- Total investments: 299
- Round size: Series A $12M–$100M; Series B $25M–$148M; Series C $22M–$140M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Leal Therapeutics — Leal Therapeutics develops novel therapeutics for patients.
- BigHat Biosciences — We use machine learning and synthetic biology to design and engineer antibody therapeutics.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 790
- Round size: Series A $8M–$116M; Series B $18M–$148M; Series C $18M–$160M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fresh fund, raised $192M in 2026
Portfolio highlights
- CoGenesys — CoGenesys is a biopharmaceutical company focused on the development of peptide- and protein-based medicines. The company develops peptide and protein-based medicines for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- Bonovo Orthopedics —
Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 2705
- Round size: Seed $850k–$9.9M; Series A $3.5M–$32M; Series B $8M–$75M
- Lead/follow: 4% lead, 96% follow
- Last fund: Likely actively investing — fresh fund, raised $90k in 2026
Portfolio highlights
- NextDroid — NextDroid - We're Doing Something Different
- Hello Patient — Healthcare AI that gets your team off the phone & in front of patients
- Alva Energy — Alva Energy is a nuclear solution based firm that aids challenges related to nuclear power offering on time delivery of nuclear megawatts.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 509
- Round size: Seed $750k–$16M; Series A $3.2M–$75M; Series B $8M–$115M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely actively investing — fresh fund, raised $400M in 2025
Portfolio highlights
- E Ink — E Ink Corp. is a supplier of electronic paper display (EPD) technologies. Products made with E Ink's electronic ink are designed to possess a paper-like high contrast appearance, ultra-low power consumption, and a thin, light form. E Ink's technology is tailored for many consumer and industrial applications including handheld devices, watches, clocks, and public information and promotional signs.
- Songbird — DropCatch.com helps you secure expiring domain names.
- Ethyreal Bio — Ethyreal Bio is an early-stage biotechnology company developing precision, mechanism-driven therapies for thyroid diseases with high unmet medical needs.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, China, India
Investor stats
- Total investments: 2171
- Round size: Series A $5.7M–$53M; Series B $10M–$85M; Series C $15M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $468M in 2024
Portfolio highlights
- Uhana — Modernize your RAN to be open and programmable, built with a rich ecosystem of partners. Learn about VMware RAN Intelligent Controller (RIC).
- erytech — ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.
- Sportsrocket — Sportsrocket is a New York-based company working to give sports fans access to live games and events, highlights, and shows. The company works with leading leagues, publishers, and rights-holders, including Major League Soccer, the PGA Tour, Scout Media, and AS Roma, to create and power customized OTT platforms. Incubated by Bedrocket Media Ventures, Sportsrocket's innovative approach is based on a proprietary sports media operating system, that offers an integrated solution for the production, distribution, management, and monetization of sports media across all platforms.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics, and genomics.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Ireland, Singapore
Investor stats
- Total investments: 575
- Round size: Series A $5M–$82M; Series B $7.5M–$100M; Series C $10M–$105M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $439M in 2025
Portfolio highlights
- ice — Ice.com is one of the leading e-commerce website that sells diamonds, engagement rings, watches, earrings and all other types of jewelry. It raised $47 million from Polaris Venture Partners and Ignition Partners. The online retailer opened its doors in 1999 and has grown to annual sales of $83.4 million.
- Living Proof — Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely newmolecules and breakthrough technologies for results you can see from across the room.
- Cushcraft Corp. — Cushcraft Corp. designs, develops, manufactures, and distributes antennas and other passive radio frequency (RF) products for broadband wireless, communications, and data connectivity solutions.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1582
- Round size: Seed $1.1M–$14M; Series A $6M–$100M; Series B $15M–$125M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Tennr — Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports.
- ngmoco — ngmoco ("Next Generation MObile COmpany") is creating and producing games for the iPhone. CEO Neil Young is a former executive from Electronic Arts, where he oversaw the development of several hit titles. Another EA vet and partner at Kleiner Perkins, Bing Gordon, sits on the board. Kleiner is an investor through its iFund.
- SolveAI —
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech, offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 1552
- Round size: Seed $1.6M–$23M; Series A $5.3M–$47M; Series B $11M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $31M in 2026
Portfolio highlights
- Seeo — Daftar akun togel resmi bisa melalui via dana, ovo, gopay, linkaja kami juga menyediakan berbagai link togel terpercaya seperti bo togel hadiah 2d 200rb, bandar togel hadiah 4d 10 juta terpercaya, situs togel resmi dan terpercaya, agen togel terpercaya, daftar bandar togel terbesar dan terpercaya, bandar togel terbesar, situs togel prize 123, bo togel bolak balik dibayar dan banyak lainnya yang kami sediakan untuk pencinta link togel resmi di Indonesia.
- Anrok — Anrok automates sales tax compliance across your financial stack, so you can grow your SaaS business in any market.
- LanzaTech — LanzaTech offers a technology platform that transforms industrial waste gases such as carbon monoxide and carbon dioxide into valuable chemical intermediates and fuels through microbial gas fermentation. The company’s process captures emissions from heavy-industry sources and uses specialized microbes to convert those gases into ethanol, which is then refined into materials such as monoethylene glycol for packaging, solvents, proteins, and sustainable aviation fuels. LanzaTech integrates its bioconversion system with industrial emitters, enabling the reuse of carbon streams that would otherwise be released into the atmosphere, and supplies downstream manufacturers in sectors including packaging, textiles, and aviation with fossil-alternative feedstocks.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 578
- Round size: Series A $20M–$128M; Series B $27M–$151M; Post-IPO Equity $35M–$275M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $120M in 2025
Portfolio highlights
- Serapha Bio —
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firms progress in life-changing medicines, technologies, and diagnostics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Japan, Israel
Investor stats
- Total investments: 181
- Round size: Series A $19M–$110M; Series B $11M–$190M; Series C $20M–$108M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
- CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 558
- Round size: Seed $1.6M–$20M; Series A $8M–$90M; Series B $15M–$112M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Innovent Biologics — Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. Theregistered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
- PlasmaGen Biosciences — PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy.Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need.They have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology.
- Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 339
- Round size: Series A $4.7M–$68M; Series B $10M–$105M; Series C $12M–$107M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — raised $5M in 2024
Portfolio highlights
- Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
- Gate Bioscience — Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease.
- Dayra Therapeutics — Dayra Therapeutics manufactures peptide based medicines.
Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital to date. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 1354
- Round size: Seed $1M–$8.1M; Series A $5M–$35M; Venture - Series Unknown $72k–$13M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $140k in 2026
Portfolio highlights
- Allara — Allara is your all-in-one virtual care team for hormonal, metabolic & gynecological conditions such as PCOS and Endometriosis.
- North.cloud — Automate your enterprise-grade cloud finance with zero effort. Our AI reduces your cloud bill by 50% without any risk, contracts, or technical work.
- Uvi — Uvi provides infrastructure that serves as a context and reasoning layer for enterprise AI agents. The platform resolves internal corporate vocabulary, tracks dependencies, and reconstructs the decision-making intent scattered across disparate systems like Jira, GitHub, and Slack. By unifying data fragments into an integrated knowledge network, it enables AI tools to process query objectives accurately while enforcing existing user access permissions at the retrieval stage.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 2217
- Round size: Seed $1.5M–$15M; Series A $8.7M–$55M; Series B $17M–$116M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely actively investing — fresh fund, raised $1.2B in 2026
Portfolio highlights
- Tennr — Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports.
- Stoïk — Stoïk is a cyber insurance company that integrates cybersecurity software with insurance protection, helping businesses manage their cyber risks effectively. Stoïk empowers brokers by offering clients comprehensive insurance policies and protection against cyber risks. Its mission is to equip brokers with the tools to help their clients insure andsafeguard against cyber threats.Stoïk's unique product simplifies the underwriting process using automated tests, replacing traditional questionnaires. It also provides continuous risk prevention through integrated cybersecurity tools and ensures swift, effective incident response with an in-house team of crisis management experts.
- Supersonik — Supersonik provides an AI-powered platform for SaaS companies to offer 24/7 interactive product demos, enabling prospects to explore and personalize demos instantly without scheduling or manual intervention.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 200
- Round size: Series A $13M–$70M; Series B $15M–$110M; Series C $14M–$105M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $450M in 2022
Portfolio highlights
- Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
- Relypsa — Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform.
- Skye Bioscience — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
Powering Breakthroughs in Life Sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 244
- Round size: Series A $10M–$80M; Series B $20M–$116M; Series C $12M–$109M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $850M in 2021
Portfolio highlights
- Orna Therapeutics — Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
- Aratana Therapeutics — Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. We are committed to bringing world class science to animal health for companion animals and the people who care for them. Our competitive advantage resides in our ability to identify, acquire and develop high-value commercialproducts for companion animals in a cost effective and efficient manner.
- Rhythm Pharmaceuticals — Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
Innova operates an early-stage venture capital fund specifically targeting the agricultural technology and farm management sectors. The firm provides pre-seed, seed, and series-A financial deployments alongside strategic scaling guidance to startups addressing agricultural biological inputs, automated labor robotics, on-farm data capture systems, and decision-support analytics. Its value proposition centers on supplying crucial initial institutional check liquidity to founders to build economically transformative tools that optimize farmer profitability and backend operation workflows. At Innova we invest in start-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired. Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, Germany, Argentina
Investor stats
- Total investments: 301
- Round size: Seed $25k–$1.5M; Pre-Seed $25k–$1.3M; Convertible Note $48k–$1.4M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $40M in 2023
Portfolio highlights
- HerdDogg — HerdDogg is a global herd health and data science platform. It is a two-part system that helps ranchers track health and proximity data from their herd. The company's device gathers the data captured by the ear tags and reports it directly to the rancher via an app or web database.
- Insignum AgTech — Insignum AgTech develops biotech plants that communicate with producers, alerting them to an illness in its early stages.
- Soiltech Wireless — Soiltech Wireless is a developer of ag-tech solutions to design electronic devices for agricultural professionals. Its product provides real-time data to drive efficiency and optimize quality. It also provides actionable data without installation hassles and creates scalable monitoring solutions for farmers.The company was founded in 2019 and isheadquartered in Rupert, Idaho.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 806
- Round size: Seed $1.8M–$10M; Series A $5.5M–$45M; Series B $7.8M–$75M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- Diligent Robotics — We build robots like Moxi that assist hospital staff with routine activities so they can focus on caring for patients.
- Setara Biosciences — Setara Biosciences combines deep expertise in Mendelian genetics, precision drug discovery, and data science to identify biologically validated targets for rare diseases with significant unmet needs targets that may also offer potential for treating more common conditions.
- GroundWork — GroundWork delivers Unified Monitoring for Real™ with an open software platform for shockingly easy integrations and customized visualizations of cloud, virtualization, network, application, server, and storage data.GroundWork Monitor is available in free (Core) and subscription versions with support (Enterprise).GroundWork was founded in 2004 andis headquartered in San Francisco, California with partners in Asia Pacific, Europe and South America.
WE BACK HEROES using technology to solve the world's biggest problems
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, Canada
Investor stats
- Total investments: 216
- Round size: Seed $2M–$13M; Pre-Seed $572k–$3.3M; Series A $8.5M–$40M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $90M in 2021
Portfolio highlights
- Wafer — Wafer is an AI optimization platform that automatically accelerates AI models by generating efficient custom GPU kernels.
- Adaption Labs — Adaption is building adaptive intelligence that continually learns. Efficient, evolving AI for any industry or language.
- Multiply Labs — Multiply Labs develops robotic systems that manufacture small-batch drugs. Current pharma production methods are manual, slow, and costly. We believe that the only way to scale them is with cloud-controlled robots.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 347
- Round size: Seed $100k–$5M; Series A $1.4M–$23M; Venture - Series Unknown $350k–$12M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $50M in 2023
Portfolio highlights
- deets — deets Inc., is a Westport, Connecticut-based mobile technology company dedicated to improving people’s lives and productivity through meaningful, on-the-go sharing and collaboration solutions. Founded in 2011 by the former leadership of successful online companies including Priceline and Hotwire, deets launched its first product in 2012. ItsMobile and Web communication software dynamically synchronizes contacts and lets users manage group conversations and collaboration all from a single mobile dashboard. For more information on deets, please visit www.sharedeets.com.
- Umbie Health — Umbie Health Corporation, an East Hartford, Conn.-based that develops a Web-based and mobile practice management application for dentists.
- Axerion Therapeutics — Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury.Axerion was established in New Haven to develop and commercialize intellectual propertylicensed from Dr. Stephen Strittmatter’s laboratory at Yale University. Axerion’s proprietary technology platforms include blockers of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimer’s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.
Lux Capital focuses on sectors such as artificial intelligence, biotechnology, advanced materials, space, and energy, backing businesses that apply scientific research to commercial applications. It provides capital alongside strategic input on product development, company building, and long-term positioning. The firm works with technical founders and research-driven teams to translate complex innovations into scalable businesses. It evaluates opportunities based on the underlying science, potential for industry impact, and feasibility of execution over extended time horizons.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 724
- Round size: Seed $1.5M–$30M; Series A $7M–$90M; Series B $13M–$150M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fresh fund, raised $10M in 2026
Portfolio highlights
- Adimab — Premier Human Antibody Discovery and Optimization
- Reflex — The open-source framework to build and deploy web apps using Python.
- Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
We are deep tech venture capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 556
- Round size: Seed $1M–$9M; Series A $5.7M–$45M; Series B $14M–$130M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely actively investing — fresh fund, raised $5M in 2026
Portfolio highlights
- CH4 Global — CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change at scale. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced bycows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in Henderson, NV.
- Kairos Power — Building the future of clean energy through iterative development and vertical integration. Kairos Power's advanced reactors deliver reliable, safe nuclear power at scale.
- BioStack — BioStack Platforms develops data infrastructure and simulation environments for healthcare and drug discovery AI. The company builds proprietary preclinical and clinical data pipelines that connect longitudinal, multimodal medical data such as EHRs, imaging, ECGs, labs, notes, audio, and outcomes. It structures this information intomachine-learning-ready datasets and workflow-aligned simulation environments rather than static text corpora. These environments support post-training, reinforcement learning, and multi-agent reasoning for medical AI systems. BioStack Platforms serves AI labs, biotechnology startups, pharmaceutical teams, and data providers that need domain-specific datasets, causal inference support, and robust reward models. Its offerings are used to test, evaluate, and train medical AI models on real-world clinical workflows before deployment in practice.
Liquid 2 Ventures is a venture capital firm that invests in early-stage startups, primarily at the pre-seed and seed stages. It provides capital, founder guidance, operational support, and access to a network of entrepreneurs, investors, and industry contacts.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Mexico, Canada
Investor stats
- Total investments: 1250
- Round size: Seed $1.1M–$9.1M; Pre-Seed $125k–$2.7M; Series A $6M–$48M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $12M in 2026
Portfolio highlights
- Albedo — Aerial quality imagery - from space.
- Eden — Eden unifies medical imaging operations with clinical AI: PACS, teleradiology, AI-assisted diagnosis and structured reporting, deployed across 2,600+ imaging departments.
- Kivo Health — Kivo Health is a telehealth lung care company that provides rehab for chronic lung disease.
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 275
- Round size: Series A $6.6M–$75M; Series B $11M–$230M; Series C $12M–$123M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $2.6B in 2024
Portfolio highlights
- ZoomInfo — ZoomInfo is the #1 GTM Platform: Marketing and sales AI plus the best B2B data. All-in-one lead generation, prospecting, market intelligence , and ABM software.
- iris labs — Iris Labs is an AI company focused on improving human wellbeing through personalized AI experiences for self-awareness, and personal growth.
- Serif Biomedicines — Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies.
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 167
- Round size: Series A $15M–$102M; Series B $22M–$120M; Series C $37M–$120M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- Kallyope — At TriGemX Bio, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine.
- Hexagon Bio — Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs.
- Circle Pharma — Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United States, Canada
Investor stats
- Total investments: 127
- Round size: Seed $350k–$3M; Series A $1.5M–$40M
- Lead/follow: 13% lead, 87% follow
- Last fund: May invest from a new fund soon — raised $20M in 2002
Portfolio highlights
- Latus Bio — Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.
- Overwatch Health — Overwatch Health offers an AI-assisted virtual rehab for cardiac and pulmonary patients.
- Palvella Therapeutics — Palvella Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular anomalies for which there are no FDA-approved therapies.
KdT Ventures is the standard for early-stage frontier science investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, India, Canada
Investor stats
- Total investments: 96
- Round size: Seed $2.6M–$13M; Series A $9M–$70M; Series B $25M–$175M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely actively investing — fresh fund, raised $4.9M in 2026
Portfolio highlights
- Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
- Skeletalis — Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis.
- Tacit Therapeutics — Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!TCA Venture Group is the largest angel investor group in the United States, possessing more than 300 members in five networks in Los Angeles, Orange County, San Diego, Central Coast, and the Inland Empire. Its members provide funding and guidance to more early-stage, high-growth companies in Southern California than any other investment group. Members invest in companies in a wide range of industries, including the life sciences, biotech, IT, services, retail, Internet, financial, software, media, consumer products, and tech startups. TCA as a whole gives companies more than just capital; they also provide counsel, mentoring, and access to an extensive network of potential investors, customers, strategic partners, and management talent. Tech Coast Angels has been ranked by CB Insights to be among the Top 20 Angel Groups in the US; TCA was also ranked as #1 for Network Centrality, meaning we have more connections than anyone! If you are in the game-changing business, we are here to help.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Seed, Venture - Series Unknown, Convertible Note
- Geography: United States, Canada, South Africa
Investor stats
- Total investments: 431
- Round size: Seed $523k–$3.7M; Convertible Note $100k–$4.5M; Venture - Series Unknown $500k–$6.2M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- EdgeX — Edokonta builds software that allows hospitals to track mobile equipment, such as IV pumps and ultrasounds. The company was founded in 2018 and based in San Diego, California.
- Nested Knowledge — Nested Knowledge is designing an interface that allows you to examine the data from a comprehensive literature review on research questions of interest. The interactive, nested features facilitate therapeutic comparisons, assist with research organization, and allow physicians to compare nuances across patient characteristics and outcomes.
- Major Medical Devices — Major Medical Devices develops next-generation vascular devices for endovascular repair and related surgical procedures.
8VC focuses its investment activities on industries such as life sciences, healthcare, logistics, manufacturing, enterprise software, and defense. Its portfolio support model aids founders in scaling transformational technologies intended to create long-term economic and societal value. The firm actively finances breakthroughs ranging from medical innovations and zero-emission transit models to security compliance and infrastructure automation.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 687
- Round size: Seed $2.5M–$13M; Series A $8M–$56M; Series B $17M–$175M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $45M in 2026
Portfolio highlights
- Dren Bio — Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
- Fragment — Fragment automates complex, exception-heavy procurement workflows with AI agents.
- Hello Patient — Healthcare AI that gets your team off the phone & in front of patients
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 102
- Round size: Seed $3.5M–$8M; Series A $15M–$75M; Series B $29M–$100M
- Lead/follow: 62% lead, 38% follow
- Last fund: May invest from a new fund soon — raised $1B in 2020
Portfolio highlights
- Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy.
- Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
- Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
Founders Fund is a San Francisco based venture capital firm investing in companies building revolutionary technologies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 1102
- Round size: Seed $1.6M–$15M; Series A $5.5M–$45M; Series B $15M–$100M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $6B in 2026
Portfolio highlights
- Quantcast — We are taking an entirely new approach to advertising on the open internet.
- Coherence Neuro — Opto Biosystems specializes in the development of innovative healthcare technologies that bridge the gap between cancer neuroscience and bioelectronics. The company focuses on creating smaller, softer, and wireless biological interfaces designed to offer a new treatment modality. By leveraging advancements in neural engineering and bioelectronics,Opto Biosystems is dedicated to building new tools that interface with the body, aiming to improve patient outcomes in the healthcare sector. Their work includes exploring the stability of thin-film electrodes for neuromodulation, highlighting their commitment to advancing medical technology.
- Watchtower Labs — Watchtower Labs is an AI-first team with a single mission: to solve the most difficult technical obstacles in vital simulations and defense.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 247
- Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Rein Therapeutics — Harnessing fibrosis, unleashing life
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of its industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 189
- Round size: Series A $12M–$100M; Series B $20M–$120M; Series C $15M–$102M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $600M in 2018
Portfolio highlights
- Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
- Flexion Therapeutics — Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.
- TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
For over two decades, Sand Hill Angels has worked openly and collaboratively with venture capital funds, other angel organizations, and the Bay Area ecosystem that fosters the growth of technology startups.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Convertible Note, Series A
- Geography: United States, Canada, India
Investor stats
- Total investments: 642
- Round size: Seed $1M–$6M; Series A $1.6M–$20M; Convertible Note $300k–$25M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Ampaire — Ampaire is making flying more accessible to more people from more airports by developing electric aircraft that are safe, clean, quiet, and less costly.
- PlusPlus — PlusPlus provides a learning and development SaaS platform for technical professionals. It automates the management of onboarding, workshops, and tech-talks at scale. With PlusPlus, companies attract and develop employees.
- Magnetic Insight — Magnetic Insight (MI) introduced magnetic particle imaging into the preclinical diagnostic research market enabling quantitative cell tracking, imaging of vascular function, detecting metastatic tumors, visualizing inflammation, CAR-T cell therapies and initial research into regenerative medicine.
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, China, France
Investor stats
- Total investments: 247
- Round size: Series A $8.1M–$191M; Series B $32M–$143M; Series C $35M–$175M
- Lead/follow: 17% lead, 83% follow
- Last fund: May invest from a new fund soon — raised $30M in 2018
Portfolio highlights
- Multiply Labs — Multiply Labs develops robotic systems that manufacture small-batch drugs. Current pharma production methods are manual, slow, and costly. We believe that the only way to scale them is with cloud-controlled robots.
- Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
- Atrium Therapeutics — Atrium Therapeutics is a clinical-stage biotechnology company developing precision RNA medicines for rare genetic cardiomyopathies. It specializes in targeted, non-viral delivery of small interfering RNA (siRNA) directly to heart muscle, building on Avidity Biosciences' Antibody Oligonucleotide Conjugate (AOC) platform to overcome non-specific tissue challenges.
Deerfield is an investment firm dedicated to advancing healthcare through investment, intelligence, and philanthropy. We work across the healthcare ecosystem, connecting people, capital, ideas, and technology in new and often unexpected ways.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series C, Venture - Series Unknown
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 306
- Round size: Series A $11M–$67M; Series C $20M–$110M; Venture - Series Unknown $3M–$120M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely actively investing — fresh fund, raised $600M in 2025
Portfolio highlights
- Neomorph — We engineer neomorphic protein surfaces to unlock targeted protein degradation.
- Setara Biosciences — Setara Biosciences combines deep expertise in Mendelian genetics, precision drug discovery, and data science to identify biologically validated targets for rare diseases with significant unmet needs targets that may also offer potential for treating more common conditions.
- SHINE Technologies — Discover SHINE Technologies' innovative approach to fusion technology, producing medical isotopes, recycling nuclear waste, and generating energy.
Keiretsu Forum is a global angel investor network with more than 2,500 accredited investor members throughout 47 chapters on 3 continents.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: United States, India, Turkey
Investor stats
- Total investments: 608
- Round size: Seed $125k–$3M; Series A $500k–$8.1M; Venture - Series Unknown $65k–$6.8M
- Lead/follow: 6% lead, 94% follow
- Last fund: May invest from a new fund soon — raised $10M in 2015
Portfolio highlights
- Bliss — Skip long waitlists and expensive therapy. Book licensed online therapists in multiple languages with culturally informed care.
- BatteryPool — BatteryPool offers battery charging solutions for EV fleets and commercial vehicles.
- Apriority Financial — In a system built for lenders, Apriority works for borrowers: no hidden lender fees, continuous rate monitoring, and we never sell your data.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they are known by leaders of portfolio companies for the expertise and deep support they provide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 97
- Round size: Series A $4.2M–$80M; Series B $21M–$112M; Venture - Series Unknown $2M–$350M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely still investing — raised $275M in 2021
Portfolio highlights
- Dren Bio — Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
- Cloverleaf Bio — Cloverleaf Bio | Developing a new class of RNA therapeutics to revolutionize cancer therapy.
- Breye Therapeutics — Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.
Investing in early-stage companies solving the biggest science and engineering challenges since 2014.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Seed, Series B
- Geography: United States, Austria, Germany
Investor stats
- Total investments: 151
- Round size: Seed $2M–$17M; Series A $6.5M–$50M; Series B $10M–$65M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- Exciva — EXCIVA GmbH is a privately held biotech company focused on development of clinical stage therapeutics for various indications in neuropsychiatry.
- Molten Salt Solutions — Molten Salt Solutions: Lithium Isotope Enrichment for Advanced Nuclear Power
- Acta Pharmaceuticals — Acta Pharmaceuticals is a biotechnology company focused on developing new therapies for early intervention and prevention of Alzheimer's disease.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 172
- Round size: Series A $16M–$200M; Series B $38M–$165M; Series C $14M–$208M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $470M in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Canada
Investor stats
- Total investments: 145
- Round size: Series A $5M–$50M; Series B $5M–$82M; Series C $8M–$88M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $30M in 2023
Portfolio highlights
- RapidPulse — Explore RapidPulse for innovative stroke treatments and technologies. Book appointments or learn about our team and clinical trials.
- 410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
- Ladder Health — Expert speech, occupational, physical, and feeding therapy for children, right from home, with flexible virtual visits and a plan that fits real life.
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United States, India, China
Investor stats
- Total investments: 2493
- Round size: Seed $2M–$26M; Series A $7M–$82M; Series B $15M–$125M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fresh fund, raised $600M in 2025
Portfolio highlights
- Tennr — Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports.
- Whizzo — Whizzo specializes in materials science-driven manufacturing of engineered fashion and technical textiles. Our expertise lies in creating and executing innovative textile blends tailored for applications across automotive, agriculture, medical textiles, and engineered fashion.
- Daletlabs — Dalet Labs is pioneering the future of e-commerce through Generative AI and visual product discovery. Its platform transforms AI-generated imagery into interactive shopping experiences featuring real, purchasable products. By combining creativity, personalization, and technology, Dalet Labs is redefining how consumers discover and shop for products.
Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Israel, The Netherlands
Investor stats
- Total investments: 95
- Round size: Seed $1M–$4M; Series A $1.3M–$10M; Venture - Series Unknown $1.1M–$9.5M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- ATDev — ATDev builds robotic mobility and assistive technology for older adults and people with disabilities
- Journey Live — Journey is shifting the way modern companies prioritize mental health. Our proactive, inclusive tools engage every employee, every day.
- Trio Pharmaceuticals — Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California.
Refactor is a seed-stage hard tech venture firm. Solo GP Zal Bilimoria writes $1-2M checks into founders building in aerospace, energy, bio, health, nuclear, defense, advanced manufacturing, and critical materials. Better Call Zal.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, New Zealand
Investor stats
- Total investments: 120
- Round size: Seed $2.7M–$11M; Series A $8M–$34M; Series B $16M–$103M
- Lead/follow: 18% lead, 82% follow
- Last fund: Likely actively investing — fresh fund, raised $50M in 2026
Portfolio highlights
- Pilgrim — Pioneering a biologically enhanced future for humanity.
- Onyx Bio — Onyx traces multiomic patient trajectories across immune health, aging, and disease, built for precision medicine.
- The Biological Computing — Biological Black Box integrates biological neurons with artificial neural networks to develop a living computer.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 415
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $35M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
- Vantia Therapeutics — Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and representbillion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
Keiretsu Capital LLC is an affiliate of the World's Leading Angel Network, Keiretsu Forum, and manages funds which enable limited partners to co-invest in the proprietary deal flow of the angel investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Convertible Note, Seed
- Geography: United States, Canada, India
Investor stats
- Total investments: 288
- Round size: Seed $400k–$2.5M; Series A $811k–$12M; Convertible Note $50k–$3M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely still investing — raised $3.7M in 2022
Portfolio highlights
- MiClient — Miclient are deal closure platform which was founded by experienced sales leaders who recognized the need for a new generation of complicated quote configuration, contract signing, renewal & payment collection at one place for SMEs, Lead Management System, B2B SaaS, CRM software, CPQ (Configure- Price- Quote)
- Healionics — Healionics aims to provide safer, more reliable means of bloodstream access for dialysis in patients with kidney failure.
- NuvOx Therapeutics — NuvOx Pharma is a clinical stage biotech company developing an innovative platform of oxygen therapeutics to treat life-threatening diseases where hypoxia plays a role.
Cultivation Capital invests in young companies whose ideas have potential to transform the way we live and work.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Australia, Canada
Investor stats
- Total investments: 339
- Round size: Seed $500k–$5M; Series A $1.4M–$15M; Venture - Series Unknown $475k–$10M
- Lead/follow: 62% lead, 38% follow
- Last fund: Likely actively investing — fresh fund, raised $6.5M in 2025
Portfolio highlights
- My FLiiP — FLiiP is the gym management software trusted by gyms in Canada and beyond. It unifies CRM, member management, billing, a branded app, and AI on one platform, the smart way to grow your gym, not just manage it.
- Force Equals — Force Equals is a Multi Agent AI planning operating system for enterprise software, ai, and business project planning. Manage Idea flow, Portfolio, Define challenges, align your team, collaborate, uncover the hidden requirements, and seamlessly hand off to development, project management or procurement workflows.
- Corstasis Therapeutics — Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Biotechnology Investor funding in United States at a glance
Stats across 21k deals from 11k investors.
Access all 10937 investors in United States Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in United States investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 10937 investors investing in United States Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!